EVGN vs PGEN vs CDNA vs NTRA vs CTVA

For growth investors, Evogene Ltd.

(EVGN) is the stronger pick with 50. 9% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Corteva, Inc. (CTVA) offers the better valuation at 49. 4x trailing P/E (21. 6x forward), making it the more compelling value choice. Analysts rate Precigen, Inc. (PGEN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Corteva, Inc.

is actually cheaper at 21. 6x.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -97. 9% for Evogene Ltd. (EVGN). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus EVGN's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Corteva, Inc.

(CTVA) is the lower-risk stock at 0. 29β versus Precigen, Inc. 's 1. 44β — meaning PGEN is approximately 391% more volatile than CTVA relative to the S&P 500. On balance sheet safety, CareDx, Inc (CDNA) carries a lower debt/equity ratio of 6% versus 87% for Evogene Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evogene Ltd.

(EVGN) is pulling ahead at 50. 9% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Evogene Ltd. grew EPS 44. 7% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, EVGN leads at 109. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corteva, Inc.

(CTVA) is the more profitable company, earning 6. 3% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps 6. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTVA leads at 15. 1% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — CDNA leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Corteva, Inc.

(CTVA) trades at 21. 6x forward P/E versus 22. 8x for CareDx, Inc — 1. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGEN: 44. 6% to $6. 00.

In this comparison, CTVA (0.

9% yield) pays a dividend. EVGN, PGEN, CDNA, NTRA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Corteva, Inc.

(CTVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 9% yield, +186. 7% 10Y return). Both have compounded well over 10 years (CTVA: +186. 7%, PGEN: -84. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EVGN (Healthcare) and PGEN (Healthcare) and CDNA (Healthcare) and NTRA (Healthcare) and CTVA (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EVGN is a small-cap high-growth stock; PGEN is a small-cap quality compounder stock; CDNA is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; CTVA is a mid-cap quality compounder stock. CTVA pays a dividend while EVGN, PGEN, CDNA, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.